Baker, R. E. et al. Infectious disease in an era of global change. Nat. Rev. Microbiol. 20, 193–205 (2022).
Pierson, T. C. & Diamond, M. S. The continued threat of emerging flaviviruses. Nat. Microbiol. 5, 796–812 (2020).
Carrera, J. P. et al. Clinical and serological findings of Madariaga and Venezuelan equine encephalitis viral infections: A follow-up study 5 years after an outbreak in Panama. Open. Forum Infect. Dis. 7, ofaa359 (2020).
Lindsey, N. P., Martin, S. W., Staples, J. E. & Fischer, M. Notes from the field: multistate outbreak of Eastern equine encephalitis Virus — United states, 2019. Morb Mortal. Wkly. Rep. 69, 50–51 (2020).
Encefalitis equina del oeste – Argentina. https://www.who.int/es/emergencies/disease-outbreak-news/item/2023-DON499.
Campos, A. S. et al. Molecular epidemiology of Western equine encephalitis virus in brazil, 2023–2024. MedRxiv Prepr Serv. Health Sci. (2024). 2024.04.15.24305848.
Souza, W. M. et al. Chikungunya: a decade of burden in the Americas. Lancet Reg. Health – Am 30 (2024).
Moraes, M. M. et al. Detection of saint Louis encephalitis virus in two Brazilian States. J. Med. Virol. 94, 776–781 (2022).
Dengue emergency in. The americas: time for a new continental eradication plan. Lancet Reg. Health – Am. 22, 100539 (2023).
Pielnaa, P. et al. Zika virus-spread, epidemiology, genome, transmission cycle, clinical manifestation, associated challenges, vaccine and antiviral drug development. Virology 543, 34–42 (2020).
Duffy, M. R. et al. Zika virus outbreak on Yap island, federated States of Micronesia. N Engl. J. Med. 360, 2536–2543 (2009).
Musso, D. et al. Zika virus in French Polynesia 2013–14: anatomy of a completed outbreak. Lancet Infect. Dis. 18, e172–e182 (2018).
Cao-Lormeau, V. M. et al. Zika virus, French polynesia, South pacific, 2013. Emerg. Infect. Dis. 20, 1085–1086 (2014).
Zanluca, C. et al. First report of autochthonous transmission of Zika virus in Brazil. Mem. Inst. Oswaldo Cruz. 110, 569–572 (2015).
Faria, N. R. et al. Establishment and cryptic transmission of Zika virus in Brazil and the Americas. Nature 546, 406–410 (2017).
WHO Director-General summarizes the outcome of the Emergency Committee. regarding clusters of microcephaly and Guillain-Barré syndrome. https://www.who.int/news/item/01-02-2016-who-director-general-summarizes-the-outcome-of-the-emergency-committee-regarding-clusters-of-microcephaly-and-guillain-barré-syndrome.
Durand, G. A. et al. Vector-Borne transmission of the Zika virus Asian genotype in Europe. Viruses 12, 296 (2020).
Dinh, L., Chowell, G., Mizumoto, K. & Nishiura, H. Estimating the subcritical transmissibility of the Zika outbreak in the state of florida, USA, 2016. Theor. Biol. Med. Model. 13, 20 (2016).
Wilder-Smith, A., Chang, C. R. & Leong, W. Y. Zika in travellers 1947–2017: a systematic review. J. Travel Med. 25, (2018).
Kraemer, M. U. G. et al. Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus. Nat. Microbiol. 4, 854–863 (2019).
Sah, R., Mohanty, A., Paul, D. & Padhi, B. K. Recent outbreak of Zika virus in India amid ongoing COVID-19 and Monkeypox outbreak: A call for action. Int. J. Surg. Lond. Engl. 109, 601–603 (2023).
Ryan, S. J. et al. Warming temperatures could expose more than 1.3 billion new people to Zika virus risk by 2050. Glob Change Biol. 27, 84–93 (2021).
Araújo, T. V. B. et al. Association between Zika virus infection and microcephaly in brazil, January to may, 2016: preliminary report of a case-control study. Lancet Infect. Dis. 16, 1356–1363 (2016).
de Freitas, P. Ocular findings in infants with microcephaly associated with presumed Zika virus congenital infection in salvador, Brazil. JAMA Ophthalmol. 134, 529–535 (2016).
Brasil, P. et al. Zika virus infection in pregnant women in Rio de Janeiro. N Engl. J. Med. 375, 2321–2334 (2016).
da Silva, I. R. F., Frontera, J. A., Bispo de Filippis, A. M., do Nascimento, O. J. M. & for the RIO-GBS-ZIKV Research Group. Neurologic complications associated with the Zika virus in Brazilian adults. JAMA Neurol. 74, 1190–1198 (2017).
Oehler, E. et al. Zika virus infection complicated by Guillain-Barré syndrome – case report, French polynesia, December 2013. Eurosurveillance 19, 20720 (2014).
Musso, D. et al. Potential sexual transmission of Zika virus. Emerg. Infect. Dis. 21, 359–361 (2015).
Barzon, L. et al. Isolation of infectious Zika virus from saliva and prolonged viral RNA shedding in a traveller returning from the Dominican Republic to italy, January 2016. Eurosurveillance 21, 30159 (2016).
Foy, B. D. et al. Probable non-vector-borne transmission of Zika virus, colorado, USA. Emerg. Infect. Dis. 17, 880–882 (2011).
Magnus, M. M. et al. Risk of Zika virus transmission by blood donations in Brazil. Hematol. Transfus. Cell. Ther. 40, 250–254 (2018).
Sirohi, D. et al. The 3.8 Å resolution cryo-EM structure of Zika virus. Science 352, 467–470 (2016).
Sager, G., Gabaglio, S., Sztul, E. & Belov, G. A. Role of host cell secretory machinery in Zika virus life cycle. Viruses 10, 559 (2018).
Sirohi, D. & Kuhn, R. J. Zika virus structure, maturation, and receptors. J. Infect. Dis. 216, S935–S944 (2017).
Zhao, H. et al. Structural basis of Zika virus-specific antibody protection. Cell 166, 1016–1027 (2016).
Hasan, S. S. et al. A human antibody against Zika virus crosslinks the E protein to prevent infection. Nat. Commun. 8, 14722 (2017).
Richner, J. M. & Diamond, M. S. Zika virus vaccines: immune response, current status, and future challenges. Curr. Opin. Immunol. 53, 130–136 (2018).
Lessler, J. et al. Assessing the global threat from Zika virus. Science 353, aaf8160 (2016).
Mason, R. A., Tauraso, N. M., Spertzel, R. O. & Ginn, R. K. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl. Microbiol. 25, 539–544 (1973).
Tricou, V. et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 12, e257–e270 (2024).
Boigard, H. et al. Zika virus-like particle (VLP) based vaccine. PLoS Negl. Trop. Dis. 11, e0005608 (2017).
Lin, H. H., Yip, B. S., Huang, L. M. & Wu, S. C. Zika virus structural biology and progress in vaccine development. Biotechnol. Adv. 36, 47–53 (2018).
Kheirvari, M., Liu, H. & Tumban, E. Virus-like particle vaccines and platforms for vaccine development. Viruses 15, 1109 (2023).
Koren, M. A. et al. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial. Lancet Infect. Dis. 23, 1175–1185 (2023).
Stephenson, K. E. et al. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infect. Dis. 20, 1061–1070 (2020).
Essink, B. et al. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials. Lancet Infect. Dis. 23, 621–633 (2023).
Bacon, A. et al. Generation of a thermostable, oral Zika vaccine that protects against virus challenge in non-human primates. Vaccine 41, 2524–2533 (2023).
Hsieh, M. S. et al. Intranasal vaccination with recombinant antigen-FLIPr fusion protein alone induces long-lasting systemic antibody responses and broad T cell responses. Front. Immunol. 12, 751883 (2021).
Serradell, M. C. et al. Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins. Nat. Commun. 10, 361 (2019).
Nash, T. E. Antigenic variation in Giardia lamblia and the host’s immune response. Philos. Trans. R Soc. Lond. B Biol. Sci. 352, 1369–1375 (1997).
Haga, K., Chen, Z., Himeno, M., Majima, R. & Moi, M. L. (eds) (Nancy), Utility of an in-vitro micro-neutralizing test in comparison to a plaque reduction neutralization test for dengue virus, japanese encephalitis virus, and zika virus serology and drug screening. Pathogens. 13, 8 (2024).
Salvo, M. A., Kingstad-Bakke, B., Salas-Quinchucua, C., Camacho, E. & Osorio, J. E. Zika virus like particles elicit protective antibodies in mice. PLoS Negl. Trop. Dis. 12, e0006210 (2018).
Mlakar, J. et al. Zika virus associated with microcephaly. N Engl. J. Med. 374, 951–958 (2016).
Styczynski, A. R. et al. Increased rates of Guillain-Barré syndrome associated with Zika virus outbreak in the Salvador metropolitan area, Brazil. PLoS Negl. Trop. Dis. 11, e0005869 (2017).
Acosta, C. J. et al. Persistence of immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: 2 years of follow-up compared with natural infection. J. Infect. Dis. 227, 1303–1312 (2023).
Chua, A. J. et al. A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of dengue and West nile virus neutralizing antibodies. Virol. J. 10, 129 (2013).
Adamson, C. S. et al. A block in virus-like particle maturation following assembly of murine leukaemia virus in insect cells. Virology 314, 488–496 (2003).
Gashti, A. B. et al. Production, purification and immunogenicity of gag virus-like particles carrying SARS-CoV-2 components. Vaccine 42, 40–52 (2024).
Ako-Adjei, D., Johnson, M. C. & Vogt, V. M. The retroviral capsid domain dictates virion size, morphology, and coassembly of gag into Virus-Like particles. J. Virol. 79, 13463 (2005).
Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474–478 (2016).
Pardi, N. et al. Zika virus protection by a single low dose nucleoside modified mRNA vaccination. Nature 543, 248–251 (2017).
Chen, C. H. et al. Intranasal immunization with Zika virus envelope domain III-Flagellin fusion protein elicits systemic and mucosal immune responses and protection against subcutaneous and intravaginal virus challenges. Pharmaceutics 14, 1014 (2022).
Mosmann, T. R. & Coffman, R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145–173 (1989).
Stevens, T. L. et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334, 255–258 (1988).
Yang, M., Dent, M., Lai, H., Sun, H. & Chen, Q. Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus. Vaccine 35, 4287–4294 (2017).
Sanchez Vargas, L. A., Mathew, A. & Rothman, L. A. T lymphocyte responses to flaviviruses — diverse cell populations affect tendency toward protection and disease. Curr. Opin. Virol. 43, 28–34 (2020).
Lima, N. S., Rolland, M., Modjarrad, K. & Trautmann, L. T. Cell immunity and Zika virus vaccine development. Trends Immunol. 38, 594–605 (2017).
Huang, H. et al. CD8⁺ T cell immune response in immunocompetent mice during Zika virus infection. J. Virol. 91, e01028–17 (2017).
Weiskopf, D. & Sette, A. T-Cell immunity to infection with dengue virus in humans. Front. Immunol. 5, (2014).
Watson, A. M. & Klimstra, W. B. T cell-mediated immunity towards yellow fever virus and useful animal models. Viruses 9, 77 (2017).
Neves, P. C. C., Santos, J. R., Tubarão, L. N., Bonaldo, M. C. & Galler, R. Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses. PLoS ONE. 8, e81953 (2013).
Lam, L. K. M., Watson, A. M., Ryman, K. D. & Klimstra, W. B. Gamma-interferon exerts a critical early restriction on replication and dissemination of yellow fever virus vaccine strain 17D-204. Npj Vaccines. 3, 1–10 (2018).
Elong Ngono, A. et al. Mapping and role of the CD8 + T cell response during primary Zika virus infection in mice. Cell. Host Microbe. 21, 35–46 (2017).
Hassert, M., Harris, M. G., Brien, J. D. & Pinto, A. K. Identification of protective CD8 T cell responses in a mouse model of Zika virus infection. Front. Immunol. 10, (2019).
Chin, W. X. et al. A single-dose live attenuated chimeric vaccine candidate against Zika virus. NPJ Vaccines. 6, 20 (2021).
Medina-Magües, L. G. et al. mRNA vaccine protects against Zika virus. Vaccines 9, 1464 (2021).
Amatya, N., Garg, A. V. & Gaffen, S. L. IL-17 signaling: the Yin and the Yang. Trends Immunol. 38, 310–322 (2017).
McGeachy, M. J., Cua, D. J. & Gaffen, S. L. The IL-17 family of cytokines in health and disease. Immunity 50, 892–906 (2019).
Jain, A., Pandey, N., Garg, R. K. & Kumar, R. IL-17 level in patients with dengue virus infection & its association with severity of illness. J. Clin. Immunol. 33, 613–618 (2013).
Becquart, P. et al. Acute dengue virus 2 infection in Gabonese patients is associated with an early innate immune response, including strong interferon alpha production. BMC Infect. Dis. 10, 356 (2010).
Acharya, D. et al. Interleukin-17A promotes CD8 + T cell cytotoxicity to facilitate West nile virus clearance. J. Virol. 91, e01529–e01516 (2016).
Zuñiga, J. et al. A unique immune signature of serum cytokine and chemokine dynamics in patients with Zika virus infection from a tropical region in Southern Mexico. Int. J. Infect. Dis. 94, 4–11 (2020).
Azevedo, R. S. S. et al. In situ immune response and mechanisms of cell damage in central nervous system of fatal cases microcephaly by Zika virus. Sci. Rep. 8, 1 (2018).
Serradell, M. C. et al. Vaccination of domestic animals with a novel oral vaccine prevents Giardia infections, alleviates signs of giardiasis and reduces transmission to humans. NPJ Vaccines. 1, 16018 (2016).
Stewart, E. L. et al. Lung IL-17A-producing CD4 + T cells correlate with protection after intrapulmonary vaccination with differentially adjuvanted tuberculosis vaccines. Vaccines 12, 128 (2024).
Derrick, S. C., Yang, A. & Cowley, S. Enhanced efficacy of BCG vaccine formulated in adjuvant is dependent on IL-17A expression. Tuberculosis 148, 102540 (2024).
Raeven, R. H. M. et al. Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination. Mucosal Immunol. 11, 1009 (2018).
Solans, L. et al. IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine. Mucosal Immunol. 11, 1753–1762 (2018).
Kimura, A., Naka, T. & Kishimoto, T. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc. Natl. Acad. Sci. 104, 12099–12104 (2007).
Restrepo, B. N. et al. Serum levels of cytokines in two ethnic groups with dengue virus infection. Am. J. Trop. Med. Hyg. 79, 673–677 (2008).
Fialho, E. M. S. et al. Maternal Th17 profile after Zika virus infection is involved in congenital Zika syndrome development in children. Viruses 15, 1320 (2023).
Maxian, O., Neufeld, A., Talis, E. J., Childs, L. M. & Blackwood, J. C. Zika virus dynamics: when does sexual transmission matter? Epidemics 21, 48–55 (2017).
Gao, D. et al. Prevention and control of Zika as a Mosquito-Borne and sexually transmitted disease: A mathematical modeling analysis. Sci. Rep. 6, 28070 (2016).
Scott, J. M. et al. Cellular and humoral immunity protect against vaginal Zika virus infection in mice. J. Virol. 92, e00038–e00018 (2018).
Kumamoto, Y. & Iwasaki, A. Unique features of antiviral immune system of the vaginal mucosa. Curr. Opin. Immunol. 24, 411–416 (2012).
Thompson, D. et al. Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge. PLoS Negl. Trop. Dis. 16, e0010588 (2022).
Berneck, B. S., Rockstroh, A., Fertey, J., Grunwald, T. & Ulbert, S. A recombinant Zika virus envelope protein with mutations in the conserved fusion loop leads to reduced antibody cross-reactivity upon vaccination. Vaccines 8, 603 (2020).
Urakami, A. et al. An envelope-modified tetravalent dengue virus-like-particle vaccine has implications for flavivirus vaccine design. J. Virol. 91, e01181–17 (2017).
Vannice, K. S. et al. Demonstrating vaccine effectiveness during a waning epidemic: A WHO/NIH meeting report on approaches to development and licensure of Zika vaccine candidates. Vaccine 37, 863–868 (2019).
Sumathy, K. et al. Protective efficacy of Zika vaccine in AG129 mouse model. Sci. Rep. 7, 46375 (2017).
Vang, L. et al. Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus. PLoS Negl. Trop. Dis. 15, e0009195 (2021).
Tebas, P. et al. ZIKA-001: safety and immunogenicity of an engineered DNA vaccine against Zika virus infection. N Engl. J. Med. 385, e35 (2021).
Slon-Campos, J. L. et al. A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. Nat. Immunol. 20, 1291–1298 (2019).
Rupil, L. L., del Carmen Serradell, M. & Luján, H. D. Production of oral vaccines based on virus-Like particles pseudotyped with protozoan-surface proteins. In Vaccine Design: Methods and Protocols, Volume 1. Vaccines for Human Diseases (ed Thomas, S.) 503–537. (Springer US, 2022).
